Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Johnson & Johnson (DJNJ3.BA)

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
370.000.00 (0.00%)
At close: 01:04PM ART
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close370.00
Open0.00
Bid250.00 x N/A
Ask384.00 x N/A
Day's Range370.00 - 370.00
52 Week Range370.00 - 370.00
Volume0
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)0.71
PE Ratio (TTM)6.58
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 27, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for DJNJ3.BA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

      NEW BRUNSWICK, N.J., August 09, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, at the Sheraton New York Hotel in New York. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).

    • Business Wire

      Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

      NEW BRUNSWICK, N.J., August 08, 2022--Johnson & Johnson (NYSE: JNJ) ("the Company") announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.

    • Business Wire

      Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference

      NEW BRUNSWICK, N.J., August 02, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

    Advertisement
    Advertisement